CA2246802C - Antigene combine a un cytomegalovirus humain et son utilisation - Google Patents

Antigene combine a un cytomegalovirus humain et son utilisation Download PDF

Info

Publication number
CA2246802C
CA2246802C CA002246802A CA2246802A CA2246802C CA 2246802 C CA2246802 C CA 2246802C CA 002246802 A CA002246802 A CA 002246802A CA 2246802 A CA2246802 A CA 2246802A CA 2246802 C CA2246802 C CA 2246802C
Authority
CA
Canada
Prior art keywords
hcmv
combined antigen
antigen
combined
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002246802A
Other languages
English (en)
Other versions
CA2246802A1 (fr
Inventor
Catharina Anna Bruggeman
Cornelis Vink
Frans Stals
Albert Ramon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mubio Products BV
Original Assignee
Universiteit Maastricht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/605,541 external-priority patent/US5800981A/en
Application filed by Universiteit Maastricht filed Critical Universiteit Maastricht
Publication of CA2246802A1 publication Critical patent/CA2246802A1/fr
Application granted granted Critical
Publication of CA2246802C publication Critical patent/CA2246802C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un antigène combiné présentant au moins trois parties de protéines de cytomégalovirus humain (HCMV). Cet antigène est caractérisé par une meilleure capacité à se lier aux anticorps spécifiques de ce cytomégalovirus, lui permettant d'être utilisé dans des dosages visant à détecter les anticorps spécifiques du cytomégalovirus et comme vaccin pour assurer une immunité de protection contre les maladies induites par le cytomégalovirus.
CA002246802A 1996-02-22 1997-02-20 Antigene combine a un cytomegalovirus humain et son utilisation Expired - Fee Related CA2246802C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/605,541 US5800981A (en) 1996-02-22 1996-02-22 Human cytomegalovirus antigen and its use
US08/605,541 1996-02-22
PCT/EP1997/000865 WO1997031117A2 (fr) 1996-02-22 1997-02-20 Antigene combine a un cytomegalovirus humain et son utilisation

Publications (2)

Publication Number Publication Date
CA2246802A1 CA2246802A1 (fr) 1997-08-28
CA2246802C true CA2246802C (fr) 2006-12-05

Family

ID=37560872

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002246802A Expired - Fee Related CA2246802C (fr) 1996-02-22 1997-02-20 Antigene combine a un cytomegalovirus humain et son utilisation

Country Status (1)

Country Link
CA (1) CA2246802C (fr)

Also Published As

Publication number Publication date
CA2246802A1 (fr) 1997-08-28

Similar Documents

Publication Publication Date Title
Urban et al. The dominant linear neutralizing antibody-binding site of glycoprotein gp86 of human cytomegalovirus is strain specific
JP4135996B2 (ja) エプスタイン−バールウイルスに関連するペプチド及び核酸配列
Utz et al. Identification of a neutralizing epitope on glycoprotein gp58 of human cytomegalovirus
Li et al. The Epstein-Barr virus (EBV) BZLF2 gene product associates with the gH and gL homologs of EBV and carries an epitope critical to infection of B cells but not of epithelial cells
EP2691422B1 (fr) Procédés et compositions permettant d'obtenir une protéine il-10 de cytomégalovirus
US5800981A (en) Human cytomegalovirus antigen and its use
IE65172B1 (en) Viral agent
Bowles et al. The ICP0 protein of equine herpesvirus 1 is an early protein that independently transactivates expression of all classes of viral promoters
US6013265A (en) Vaccine composition for herpes simplex virus and methods of using
FI113298B (fi) Diagnostinen reagenssi, menetelmä ja testitarvikesarja EBV:n vasta-aineiden detektoimiseksi
Gönczöl et al. Humoral immune response to cytomegalovirus Towne vaccine strain and to Toledo low-passage strain
EP0769056B1 (fr) VARIANTES NON EPISSABLES DES gp 350 ET 220
KR100224331B1 (ko) 조환수두 대상포진바이러스 및 그 제작방법
US5807557A (en) Soluble herpesvirus glycoprotein complex
Kropff et al. Identification of the gene coding for rhesus cytomegalovirus glycoprotein B and immunological analysis of the protein
US6197497B1 (en) Immunoassay for herpes simplex virus
Cohen et al. Identification of viral polypeptides involved in pseudorabies virus ribonucleotide reductase activity
CA2246802C (fr) Antigene combine a un cytomegalovirus humain et son utilisation
Xu et al. Assessment of antigenicity and genetic variation of glycoprotein B of murine cytomegalovirus
US20040234542A1 (en) Recombinant orf2 proteins of the swine hepatitis e virus and their use as a vaccine and as a diagnostic reagent for medical and veterinary applications
Chan et al. Proliferative T-cell response to glycoprotein B of the human herpes viruses: the influence of MHC and sequence of infection on the pattern of cross-reactivity
ES2341061T3 (es) Regiones inmunorreactivas de la glicoproteina gpii del virus de la varicela zoster (vzv).
Liu et al. Antibody against the Epstein‐Barr virus BHRF1 protein, a homologue of Bcl‐2, in patients with nasopharyngeal carcinoma
Gretch et al. Expression of a human cytomegalovirus glycoprotein multigene family
JP2883085B2 (ja) Hcmvの糖タンパク質類、それらに対する抗体類及びhcmvワクチンの産生法、並びにそれらのための組換えベクター

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed